Browsing
     by title


0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

or enter first few letters:   
OK
Peer Reviewed
See detailLes hernies discales intradurales
Martin, Didier ULg; Mouchamps, M.; Collignon, Jacques ULg et al

Conference (1987, March 14)

Detailed reference viewed: 5 (0 ULg)
Peer Reviewed
See detailHeroic Fantasy et modernité: la problématique de la quête chez Michael Moorcock et Samuel R. Delany
Delville, Michel ULg

in Sources: Revue d'Etudes Anglophones (2001), 11

Detailed reference viewed: 96 (4 ULg)
Peer Reviewed
See detailHeroin-Assisted Treatment as a treatment of criminal behaviour?
Demaret, Isabelle ULg; Litran, Géraldine; ANSSEAU, Marc ULg et al

Conference (2010, September 08)

Background: TADAM, a randomised controlled trial of heroin-assisted treatment, will begin in Liège, Belgium, in 2010. This trial will compare two groups of patients: one in a heroin-assisted treatment and ... [more ▼]

Background: TADAM, a randomised controlled trial of heroin-assisted treatment, will begin in Liège, Belgium, in 2010. This trial will compare two groups of patients: one in a heroin-assisted treatment and the other in oral methadone treatment. In this new medical treatment, the criminal behaviour of the patients will also be assessed. It is one of the three efficacy criteria. Why? Methodology: We based our presentation on papers published on heroin-assisted treatment concerning changes in criminal behaviour. Results: Heroin-assisted treatment of treatment resistant heroin addicts has been successfully tested in six countries: Switzerland, The Netherlands, Spain, Germany, Canada and United-Kingdom. Each country has also assessed the criminal behaviour before and after the treatment with better results for heroin-assisted treatment than for methadone treatment. Conclusion: HAT seems a good way to treat criminal behaviour of a group: severely heroin addicts who already tried other treatments. [less ▲]

Detailed reference viewed: 13 (4 ULg)
Full Text
Peer Reviewed
See detailHeroin-assisted treatment showed better efficacy than methadone
ANSSEAU, Marc ULg; Demaret, Isabelle ULg

Poster (2014, May 04)

Background: A fraction of patients receiving methadone treatment pursues their use of street heroin. In Switzerland, a new treatment with prescribed diacetylmorphine (pharmaceutical heroin) was developed ... [more ▼]

Background: A fraction of patients receiving methadone treatment pursues their use of street heroin. In Switzerland, a new treatment with prescribed diacetylmorphine (pharmaceutical heroin) was developed to help these heroin addicts resistant to methadone treatment to decrease their street heroin use. In this heroin-assisted treatment (HAT), diacetylmorphine is prescribed to severe heroin user and diacetylmorphine is administered by patients under the supervision of nurses in a specific centre. Six randomised controlled trials compared HAT to methadone treatment: in Switzerland, The Netherlands, Spain, Germany, Canada and United- Kingdom. HAT showed better efficacy than methadone. Patients used less street heroin, their health improved and their criminal behaviour decreased. A new trial assessed in Belgium the feasibility and efficacy of this treatment compared to methadone treatment. Methods: The TADAM (Treatment Assisted by Diacetylmorphine) was an open label randomised controlled trial developed on the Swiss model of HAT developed in 1994. Main inclusion criteria were 5 years of heroin addiction, (almost) daily use of street heroin and a previous attempt of methadone treatment. As in the Dutch experiment, patients could choose to inhale or to inject diacetylmorphine in the new HAT centre. HAT was stopped after 12 months and the best available treatment was offered to the patient. The research team assessed subjects every three months with standardised questionnaires (EuropASI, MAP-HSS, SCL-90-R) and questions on involvement in a criminal milieu. We completed our reported data with toxicological analysis and criminal proceedings. Results: 74 subjects were randomised in the trial: 36 in the experimental group and 38 in the control group. According to the primary efficacy criterion, the experimental group counted at least 30% more responders than the control group after 3 months (p<0.05), 6 months (p<0.05) and 9 months (p<0.01). At the 12 month assessment, the number of responders was still higher in the experimental group but the difference (11%) was no more significant (p=0.35). At the 12 month assessment, the condition of patients in the experimental group worsened compared to the 9 month assessment. This effect was not seen in the control group were patients could continue their methadone treatment after the 12 months. Conclusion: As in other countries, HAT is an effective treatment for severe heroin addicts resistant to methadone treatment. However, a predetermined duration of 12 month counteracts the efficacy of this treatment. [less ▲]

Detailed reference viewed: 11 (1 ULg)
See detailHéroïne - Détermination du délai entre le prélèvement et la consommation
Dubois, Nathalie ULg

Scientific conference (2008, October)

Detailed reference viewed: 7 (1 ULg)
Full Text
Peer Reviewed
See detailL'héroïne
Demaret, Isabelle ULg; Lemaître, André ULg; Ansseau, Marc ULg

in Revue Médicale de Liège (2013), 68(5-6), 287

Summary : Heroin (or diacetylmorphine), a depressant of the nervous central system, is a semi-synthetic opiate. Its main adverse effect, respiratory depression, can lead to death, especially after an ... [more ▼]

Summary : Heroin (or diacetylmorphine), a depressant of the nervous central system, is a semi-synthetic opiate. Its main adverse effect, respiratory depression, can lead to death, especially after an intravenous injection. By loss of tolerance, an overdose can be lethal following heroin use after a period of abstinence (voluntary or not). Mortality rate among heroin users is between 1 and 3%. Addiction, following a regular and continuous use, occurs in less than a quarter of persons who ever tried heroine. Heroin addicts often present with different problems (for instance, a criminal behaviour), without any obvious link with addiction. For a fraction of the addicts, addiction becomes a chronic relapsing disease, requiring a long term maintenance substitution therapy. However, relapses and sometimes continuous heroin use are frequent. For treatment resistant and severe heroin addicts, heroinassisted treatment can be a solution. Despite the numerous available therapies, heroin is considered to be the drug with the most negative effects on the user. [less ▲]

Detailed reference viewed: 40 (15 ULg)
See detailUn héros dans les étoiles : l'ambiguïté d'Orion
Renaud, Jean-Michel ULg

Scientific conference (2001, March 21)

Detailed reference viewed: 13 (0 ULg)
See detailHéros et héroïnes dans les mythes et les cultes grecs. Actes du colloque de Valladolid (mai 1999)
Pirenne-Delforge, Vinciane ULg

Book published by Centre International d'Etude de la Religion Grecque Antique (2000)

Detailed reference viewed: 51 (9 ULg)
Full Text
Peer Reviewed
See detailL'herpes labial récidivant. Comment traiter et prévenir au mieux.
Nikkels, Arjen ULg; Pierard, Gérald ULg

in Revue Médicale de Liège (2006), 61(5-6), 442-7

Labial herpes is a recurrent muco-cutaneous disorder caused by the herpes simplex virus (HSV), particularly the HSV type I. It affects 10 to 30% of the adult population. The recurrence rate varies from ... [more ▼]

Labial herpes is a recurrent muco-cutaneous disorder caused by the herpes simplex virus (HSV), particularly the HSV type I. It affects 10 to 30% of the adult population. The recurrence rate varies from episodic events to monthly recurrences. Several triggering factors have been identified. They include physical factors such as ultraviolet radiations and any local traumatism such as dental and neurosurgical interventions, and dermo-cosmetic procedures of the face. Hormonal factors are also involved including those related to menses and pregnancy. Psychogenic factors, particularly severe stress are also involved. Any other intercurrent infection may also be complicated by recurrent labial herpes. The management of recurrent labial herpes currently relies on the identification and possible avoidance of triggering factors, and on the use of antiviral agents. There is no curative treatment available so far. [less ▲]

Detailed reference viewed: 213 (5 ULg)
Full Text
Peer Reviewed
See detailHerpes Simplex Virus Infections of the Nipple
EL HAYDERI, Lara ULg; CAUCANAS, Marie ULg; NIKKELS, Arjen ULg

in Open Dermatology Journal (The) (2012)

The usual sites of herpes simplex virus (HSV) type 1 and 2 infections are orolabial and anogenital, respectiverly. HSV infection of the nipple and periareolar area is exceptional but probably ... [more ▼]

The usual sites of herpes simplex virus (HSV) type 1 and 2 infections are orolabial and anogenital, respectiverly. HSV infection of the nipple and periareolar area is exceptional but probably underrecognized. Typical features include severe pain and erosive or ulcerated erythematous confluent clusters of lesions of the nipple and periareolar area. It is usually unilateral and not recurring. HSV infection of the nipple is originating from autoinoculation, sexual transmission or breastfeeding. Diagnosis is often delayed. The Tzanck smear is the most rapid and adequate method of dagnosis. Immunohistochemistry enables viral identification. The treatment relies on topical disinfection and oral antiviral therapy, such as aciclovir, famciclovir or valaciclovir. Scarring is uncommon. [less ▲]

Detailed reference viewed: 112 (0 ULg)
Full Text
Peer Reviewed
See detailHERPES SIMPLEX VIRUS REACTIVATION AND DENTAL PROCEDURES
EL HAYDERI, Lara ULg; DELVENNE, Philippe ULg; ROMPEN, Eric ULg et al

in Clinical Oral Investigations (2013)

Objectives : Dental extraction is reportes to trigger recurrent herpes labialis (RHL). Aim : This aims to prospectively study the clinical occurrence of RHL and the oral herpes simplex virus type 1 (HSV-1 ... [more ▼]

Objectives : Dental extraction is reportes to trigger recurrent herpes labialis (RHL). Aim : This aims to prospectively study the clinical occurrence of RHL and the oral herpes simplex virus type 1 (HSV-1) viral shedding before and 3 days after different dental procedures. Materials and methods : Oral HSV-1 DNA was measured by real-time PCR before and 3 days after dental procedures of the inferior dentition in 57 immunocometent patients (mean age 32.4 years) who were selected and divided into four distinct subgroups (dental inspection without anesthesia, n=14; molar extraction under local anesthesia, n=15; and molar extraction under general anesthesia, n=9) and compared to 32 healthy controls (mean age 33 years). Results : None of the patients suffered from RHL at day 3. Oral HSV-1 DNA was detected before and after procedure in 1.7 % (1/57) and 5.3 % (3/57), respectively [dental inspection without anesthesia, 5.3 % (1/19); molar extraction under local anesthesia, 6.7 % (1/15); and molar extraction under general anesthesia, 11 % (1/9)]. None of the controls presented RHL or detectable oral HSV-1 DNA. There was no statistically significant difference between the study groups and controls. [less ▲]

Detailed reference viewed: 38 (11 ULg)
Full Text
Peer Reviewed
See detailHERPES SIMPLEX VIRUS TYPE_i AND PYOGENIC GRANULOMA : A VASCULAR ENDOTHELIAL GROWTH FACTOR-MEDIATED ASSOCIATION?
EL HAYDERI, Lara ULg; PAUROBALLY, Dilshad ULg; FASSOTTE, Marie-France ULg et al

in Case Reports in Dermatology (2013), 5

Pyogenic granuloma (PG) is a vascular endothelial growth factor (VEGF)-related neoangiogenic process. Minor trauma, chronic irritation, certain drugs and pregnancy may favor PG. Viral triggers have not ... [more ▼]

Pyogenic granuloma (PG) is a vascular endothelial growth factor (VEGF)-related neoangiogenic process. Minor trauma, chronic irritation, certain drugs and pregnancy may favor PG. Viral triggers have not been reported up to date. A 52-year-old woman with hairly-cell leukemia presented because of a3-month history of a giant pseudotumoral lesion on her left cheek. All prior antibacterial, antifungal and anti-inflammatory treatments had failed. Histology revealed PG with sparse and isolated epithelial cell aggregates. Immunohistochemistry (IHC) identified herpes simplex virus type-I (HSV-I) antigens in the nuclei and cytoplasm of normal-appearing as well as cytopathic epithelial cells, suggesting a chronic, low-productive HSV infection. No HSV-I signal was evidenced in the endothelial cells of the PG. Furthermore, IHC revealed VEGF in the HSV-I infected epithelial cells as well as within the PG endothelial cells. These results incited oral treatment with valaciclovir, and the PG promptly resolved after 2 weeks. These findings suggest that a chronic HSV-I infection might play and indirect, partial role in neoangiogenesis, presumably via HSV-I infection-related stimulation of keratinocytic VEGF production. [less ▲]

Detailed reference viewed: 3 (0 ULg)
Full Text
Peer Reviewed
See detailL'herpes virus de type 6. Quelle attention mérite-t'il en medecine générale?
Nikkels, Arjen ULg; Pierard, Gérald ULg

in Revue Médicale de Liège (2006), 61(5-6), 317-21

The human herpesvirus 6 (HHV6) is a member of the beta-herpes viridae family. The primary infection is usually asymptomatic and commonly occurs during childhood. The clinical form is called exanthema ... [more ▼]

The human herpesvirus 6 (HHV6) is a member of the beta-herpes viridae family. The primary infection is usually asymptomatic and commonly occurs during childhood. The clinical form is called exanthema subitum, or roseala infantum or the 6th disease. This biphasic disorder usually runs a benign course and requires no antiviral treatment. However, the HHV6 reactivation can lead to serious systemic diseases, especially encephalopathy, that may be fatal in the immunocompromised or grafted patient. In seronegative pregnant women, a primary HHV6 infection contracted from a child with roseola infantum can lead, in rare instances, to spontaneous abortion during the first trimester, or produce neurological complications in the newborn after HHV6 transplacental infection. Aciclovir, ganciclovir (GCV), foscarnet and cidofovir show anti-HHV6 in vitro efficacy, but GCV is currently the first line agent when of HHV6 infection is diagnosed in the immunocompromised patient. [less ▲]

Detailed reference viewed: 68 (4 ULg)
Full Text
Peer Reviewed
See detailHerpes zoster
Nikkels, Arjen ULg; Pierard, Gérald ULg

in Acta Dermato Venereologica (1998), 78

Detailed reference viewed: 11 (0 ULg)
Full Text
See detailHerpes zoster in patients treated with biologicals
FAILLA, Valérie ULg; JACQUES, Jessica ULg; CASTRONOVO, Charlotte ULg et al

in Dermatology (2012)

Background : The incidence and severity of herpes zoster (HZ) appear increased in patients receiving tumor necrosis factor-alpha antagonists. Objective : To study the incidence and clinical features of HZ ... [more ▼]

Background : The incidence and severity of herpes zoster (HZ) appear increased in patients receiving tumor necrosis factor-alpha antagonists. Objective : To study the incidence and clinical features of HZ in 1,220 patients (4.206 patient-years) receiving either adalimumab, etanercept, infliximumab, rituximab or ustekinumab. Results: Twenty-two HZ cases were identified (1.26% of total cohort; adalimumab: 11/1,546 patient-years, incidence rate (IR) 7.1; etanercept: 4/789 patient-years, IR5.1; rituximab: 1/168 patient-years, IR 5.2; ustekinumab: 2/37 patient-years, IR53.5; infliximab: 4/1.666 patient-years, IR 2.4). The time to event varied widely (1.5-108 months). Extensive HZ was reported in 45 and 32% of the cases, respectively. Persistent postzoster neuralgia (PHN;>6months) was observed in 5/20 patients. Conclusions: The Hz incidence was 2.1-fold higher among patients over 60 years, compared with a reference population, although not statistically significant. Severe, multidermatomal HZ and persistent PHN were common. [less ▲]

Detailed reference viewed: 22 (4 ULg)
Full Text
Peer Reviewed
See detailHerpesviridae granulomas. Letter
Nikkels, Arjen ULg; Pierard, Gérald ULg

in European Journal of Dermatology (1996), 6(5), 394

Detailed reference viewed: 4 (0 ULg)
Full Text
Peer Reviewed
See detailL’herpèsvirose canine
Ronsse, V.; Poulet, H.; Verstegen, J. et al

in Annales de Médecine Vétérinaire (2003), 147(2, APR-MAY), 65

Canine herpesvirus is known to be a causal agent of reproduction disorders and diseases of the upper respiratory system. Subclinical infections are also frequently observed. The interest for the virus has ... [more ▼]

Canine herpesvirus is known to be a causal agent of reproduction disorders and diseases of the upper respiratory system. Subclinical infections are also frequently observed. The interest for the virus has risen in recent years especially since latency has been demonstrated and a new vaccine has been developed. In this review article we will successively deal with virus characteristics, epidemiology, pathogenesis, clinical signs, diagnosis as well as therapy and prevention. [less ▲]

Detailed reference viewed: 21 (2 ULg)